Vestal Point Capital LP Has $46.32 Million Stock Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Vestal Point Capital LP lifted its position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 73.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 4,000,000 shares of the specialty pharmaceutical company’s stock after buying an additional 1,700,000 shares during the period. KalVista Pharmaceuticals comprises 3.5% of Vestal Point Capital LP’s portfolio, making the stock its 7th largest holding. Vestal Point Capital LP owned about 9.25% of KalVista Pharmaceuticals worth $46,320,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. nVerses Capital LLC purchased a new position in shares of KalVista Pharmaceuticals in the second quarter worth $25,000. China Universal Asset Management Co. Ltd. raised its position in KalVista Pharmaceuticals by 67.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company’s stock worth $96,000 after buying an additional 3,328 shares during the last quarter. Intech Investment Management LLC bought a new position in KalVista Pharmaceuticals during the 3rd quarter valued at about $126,000. SG Americas Securities LLC purchased a new stake in shares of KalVista Pharmaceuticals during the 3rd quarter valued at about $153,000. Finally, Quest Partners LLC bought a new stake in shares of KalVista Pharmaceuticals in the third quarter worth approximately $175,000.

KalVista Pharmaceuticals Trading Up 1.1 %

Shares of KalVista Pharmaceuticals stock opened at $10.09 on Friday. KalVista Pharmaceuticals, Inc. has a 1-year low of $7.39 and a 1-year high of $16.88. The company’s fifty day simple moving average is $10.98 and its 200-day simple moving average is $11.93.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share for the quarter, beating the consensus estimate of ($0.91) by $0.04. As a group, research analysts predict that KalVista Pharmaceuticals, Inc. will post -2.7 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Benjamin L. Palleiko sold 7,352 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $12.19, for a total value of $89,620.88. Following the transaction, the chief executive officer now directly owns 250,800 shares in the company, valued at $3,057,252. The trade was a 2.85 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Paul K. Audhya sold 8,077 shares of the stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.26, for a total value of $74,793.02. Following the sale, the insider now owns 94,199 shares of the company’s stock, valued at $872,282.74. This represents a 7.90 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 32,016 shares of company stock worth $319,344. Company insiders own 10.50% of the company’s stock.

Wall Street Analysts Forecast Growth

KALV has been the topic of several research reports. Needham & Company LLC restated a “buy” rating and issued a $32.00 target price on shares of KalVista Pharmaceuticals in a report on Friday, September 6th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a report on Monday, October 7th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, September 9th.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).